StockMarketWire.com - GlaxoSmithKline said it had submitted an application for a drug that treats renal anaemia in patients with chronic kidney disease to the Japanese health regulator.

'Around 3.5 million patients in Japan have anaemia associated with renal disease which can result in weakness and fatigue. We are excited about our first regulatory filing for daprodustat which, if approved, will provide a new and convenient oral treatment option for these patients,' said Dr Hal Barron, Chief Scientific Officer and President R&D, GSK.

The Japanese New Drug Applicationfor daprodustat was primarily based on positive data from the phase 3 programme conducted in Japan.




At 8:58am: [LON:GSK] GlaxoSmithKline PLC share price was +1.5p at 1667.9p



Story provided by StockMarketWire.com